OncoMatch/Clinical Trials/NCT05789082
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
Is NCT05789082 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Divarasib · Pembrolizumab · Carboplatin · Cisplatin · Pemetrexed — The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS g12c
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KRAS inhibitor
Prior treatment with a KRAS G12C inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope National Medical Center · Duarte, California
- City of Hope - Seacliff · Huntington Beach, California
- City of Hope at Irvine Lennar · Irvine, California
- UCSD Moores Cancer Center · La Jolla, California
- City of Hope - Long Beach Elm · Long Beach, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05789082 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require KRAS?
Yes, KRAS g12c is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify